Phase 3 SKYLARK Study of Zuranolone in Postpartum ... | 化學工廠資訊網
2022年6月8日—Zuranoloneisaninvestigationaltwo-week,once-dailyoraldrugbeingstudiedinpostpartumdepressionandmajordepressivedisorder.
Zuranolone is an investigational two-week, once-daily oral drug being studied in postpartum depression and major depressive disorder. Samantha Meltzer-Brody, MD, MPH, Chair of the UNC Department of Psychiatry and Director of the UNC Center for Women’s Mood Disorders, is the principal investigator for the UNC Medical Center site of this study.
Samantha Meltzer-Brody, MD, MPHPostpartum depression (PPD) is one of the most common medical complications during and after pregnancy impacting approximately 1 in 8 women annually in the U.S. While recognized by the U.S. Department of Health and Human Services as a high-priority public health issue, screening rates vary and nearly 70% of women with PPD may go undiagnosed.
There is currently only one drug, ZULRESSO® (brexanolone) injection, approved by the U.S. Food and Drug Administration (FDA) specifical...
Effect of Zuranolone vs Placebo in Postpartum Depression | 化學工廠資訊網
New Analyses Strengthen Efficacy | 化學工廠資訊網
Phase 3 SKYLARK Study of Zuranolone in Postpartum ... | 化學工廠資訊網
Sage Therapeutics and Biogen Announce that the Phase 3 ... | 化學工廠資訊網
Zuranolone - SAGE Therapeutics | 化學工廠資訊網
Zuranolone | 化學工廠資訊網
Zuranolone shows promise as episodic treatment for depression | 化學工廠資訊網
【新北市】瑞台生醫科技股份有限公司
新北市化工廠有哪些?本篇為大家整理位於新莊區化成路540號之1七樓之2的「瑞台生醫科技股份有限公司」相關資訊,用列表的方...